Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A hereditary sensory neuropathy characterized by adult onset of progressive peripheral sensory loss, progressive hearing impairment, and early-onset dementia that has material basis in heterozygous mutation in the DNMT1 gene on chromosome 19p13.
Features include always present findings: Sensory neuropathy; and very common findings: Hearing loss (hearing impairment). 16 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 9 | Hyporeflexia, Brain shrinkage (cerebral atrophy), Memory problems (memory impairment) |
Muscles | 2 | Brain shrinkage (cerebral atrophy), Distal muscle weakness |
Ears | 2 | Hearing loss (hearing impairment), Inner ear hearing loss (sensorineural hearing impairment) |
Bones and joints | 1 | Bone infection (osteomyelitis) |
Age of onset: adulthood.
DNMT1-related disorder is a degenerative disorder of the central and peripheral nervous systems characterized by sensory impairment, sudomotor dysfunction (loss of sweating), dementia, and sensorineural hearing loss. In some individuals, late-onset narcolepsy/cataplexy syndrome presents as the prominent manifestation along with: ataxia that appears to be cerebellar in nature, deafness, sensory neuropathy, and memory loss . Affected persons are normal in their youth but begin to manifest progressive findings, such as sensorineural hearing loss, sensory neuropathy, and/or narcolepsy/cataplexy, by their late teens or early 20s. In a cohort of 45 affected individuals, the average age of onset was estimated to be 37.
Source: GeneReviews — "DNMT1-Related Disorder"
DNMT1 encodes DNA methyltransferase 1 (1,616 aa). DNA methyltransferase that methylates CpG residues. Preferentially methylates hemimethylated DNA. Highest expression in Cells EBV-transformed lymphocytes (84.0 TPM) and Testis (56.6 TPM).
Hereditary sensory neuropathy-deafness-dementia syndrome is associated with mutations in the DNMT1 gene on chromosome 19.
The DNMT1 protein participates in SUMOyation of DNMT1 with SUMO1, STAT3-dependent DNMT1 gene expression, and DNMT1 methylates cytosine in hemimethylated DNA pathways.
DNMT1 is classified as a druggable target (Clinically Actionable, Drug Resistance, Druggable Genome, and Enzyme categories) with score 2.3.
The penetrance of DNMT1 disorder is 100% in both males and females. However, age of onset and rate of progression vary between individuals.
Source: GeneReviews — "DNMT1-Related Disorder"
The phenotype of DNMT1-related disorder is a continuum ranging from hereditary sensory and autonomic neuropathy type 1E (HSAN1E) to autosomal dominant cerebellar ataxia, deafness, and narcolepsy (ADCA-DN).
DNMT1 disorder should be suspected in individuals with the following clinical, electrophysiologic, and neuroimaging findings and family history.
Clinical findings
Source: GeneReviews — "DNMT1-Related Disorder"
Autosomal dominant hereditary sensory and autonomic neuropathies are genetically heterogeneous, but hereditary sensory and autonomic neuropathy type IE (HSAN1E) that includes dementia and hearing loss represents a unique phenotype. The combination of neuropathy with hearing loss can be confused with some forms of Charcot-Marie-Tooth, and the dementia is similar to that found in frontotemporal dementia or, more commonly, global cognitive disorder. However, if it is recognized that the neuropathy, hearing loss, and dementia represent a single syndrome, the diagnosis should be clear when it occurs in persons younger than age 50 years. See Hereditary Sensory and Autonomic Neuropathy: OMIM Phenotypic Series to view genes associated with HSAN in OMIM.
Source: GeneReviews — "DNMT1-Related Disorder"
Genetic testing for DNMT1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hereditary sensory neuropathy-deafness-dementia syndrome has been reported in the published literature.
No approved treatments are currently available for hereditary sensory neuropathy-deafness-dementia syndrome. The disease remains an area of unmet medical need.
To establish the extent of disease and needs of an individual diagnosed with DNMT1-related disorder, the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended:
Neurologic examination to determine the extent of sensory involvement, including sensory testing and observation for skin ulceration
Past medical history to determine extent of autonomic involvement
Evaluation of central nervous system involvement, using tests of cognitive function and brain imaging
Audiologic examination to determine if hearing loss is present and, if present, its type and severity
Consultation with a clinical geneticist and/or genetic counselor
No cure for DNMT1 disorder currently exists. The emphasis of management is to help parents and affected individuals understand the sudomotor defect and injury prevention when sensory impairment is significant. To prevent injury to extremities with decreased sensation, protect the skin with appropriate socks and shoes and avoid exposure of feet to hot water. Because hearing loss may be severe, initial use of hearing aids and/or assistive communication methods may be needed. See also Hereditary Hearing Loss and Deafness Overview. Sedative or antipsychotic drugs help to reduce extreme restlessness, roaming behavior, delusions, and hallucinations associated with dementia.
Source: GeneReviews — "DNMT1-Related Disorder"
Avoid sharp objects and hot water, which may damage skin.
Source: GeneReviews — "DNMT1-Related Disorder"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "DNMT1-Related Disorder"
View trials for hereditary sensory neuropathy-deafness-dementia syndrome
Sensory impairment. Examine feet on a daily basis to screen for skin injury. Dementia. Perform annual routine clinical testing for dementia:
Observation of behavior
Use of tools such as the Mini Mental State Exam (MMSE)
Hearing loss. Perform annual audiogram.
Source: GeneReviews — "DNMT1-Related Disorder"
Phenotype severity distribution: 1 always present feature, 1 very common feature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for hereditary sensory neuropathy-deafness-dementia syndrome.
75 publications have been identified in PubMed for hereditary sensory neuropathy-deafness-dementia syndrome. Research spans Case Report / Case Series (30%), Review / Meta-Analysis (27%), and Epidemiology / Natural History (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 22 | 30% |
Research summaries | 20 | 27% |
Disease patterns and progression | 13 | 18% |
Laboratory research | 12 | 16% |
Testing and diagnosis research | 3 | 4% |
New treatment approaches | 3 | 4% |
Clinical study results | 1 | 1% |
Yaukey J (2026). [PMID: 41367223](https://pubmed.ncbi.nlm.nih.gov/41367223/). *Muscle Nerve*. [Review / Meta-Analysis]
Tsuruda T (2026). [PMID: 41711216](https://pubmed.ncbi.nlm.nih.gov/41711216/). *ESC Heart Fail*. [Epidemiology / Natural History]
Kutija Fučkar I (2026). [PMID: 42074586](https://pubmed.ncbi.nlm.nih.gov/42074586/). *Genes (Basel)*. [Epidemiology / Natural History]
Aynaashe A (2026). [PMID: 41621017](https://pubmed.ncbi.nlm.nih.gov/41621017/). *Amino Acids*. [Review / Meta-Analysis]
Liu C (2026). [PMID: 42196291](https://pubmed.ncbi.nlm.nih.gov/42196291/). *Int J Mol Sci*. [Review / Meta-Analysis]
Lenggenhager-Krakoski N (2026). [PMID: 41479298](https://pubmed.ncbi.nlm.nih.gov/41479298/). *Eur J Anaesthesiol*. [Case Report / Case Series]
Braun N (2026). [PMID: 41704161](https://pubmed.ncbi.nlm.nih.gov/41704161/). *Pediatr Dermatol*. [Review / Meta-Analysis]
Feenstra RA (2026). [PMID: 41488770](https://pubmed.ncbi.nlm.nih.gov/41488770/). *iScience*. [Review / Meta-Analysis]
Dougnon G (2026). [PMID: 40858777](https://pubmed.ncbi.nlm.nih.gov/40858777/). *Mol Psychiatry*. [Basic Science / Preclinical]
Bjelica B (2026). [PMID: 42052752](https://pubmed.ncbi.nlm.nih.gov/42052752/). *J Peripher Nerv Syst*. [Gene Therapy / Novel Therapeutics]
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 2:37 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning hereditary sensory neuropathy-deafness-dementia syndrome
Updated Feb 14, 2026
Recent research identifies mitochondrial energetic failure as a key factor in FLVCR1-related sensory neuropathy. This discovery could pave the way for targeted therapies addressing the underlying mitochondrial dysfunction.